VO2 Max and Longevity: Separating Durable Evidence From Expensive Hope

Longevity is searched roughly fifty thousand times a month, and the gap between what sells and what is supported has rarely been wider. Here is the current split, judged only on human evidence.

Strong human evidence

• Cardiorespiratory fitness: among the strongest single predictors of all-cause mortality that behaviour can change.
• Resistance training and preserved muscle mass, particularly after fifty.
• Sleep regularity — timing consistency now looks as important as total duration.
• Blood pressure, lipid and glucose control, unfashionable and repeatedly decisive.
• Social connection, with effect sizes comparable to major clinical risk factors.

Promising but unresolved

Senolytics that clear ageing cells remain compelling in animals with early human trials underway. Epigenetic clocks measure something real but are noisy enough that a single consumer test can shift several years on a retest. Metabolic repurposing of existing drugs is under study in large trials whose results will matter more than any current protocol.

If an intervention promises to reverse ageing and can be bought without a clinician, the evidence for it is almost certainly weaker than the marketing.

How to evaluate a longevity claim

Look for randomised human data, a hard endpoint rather than a biomarker, replication by an independent group, and disclosure of who funded the work. Most of the popular protocol stack fails at least two of those tests, which does not make it harmful — only unproven and often expensive.